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Abstract
Background: Mutations in the mitochondrial DNA (mtDNA) have been reported in a wide
variety of human neoplasms. A polynucleotide tract extending from 303 to 315 nucleotide positions
(D310) within the non-coding region of mtDNA has been identified as a mutational hotspot of
primary tumors. This region consists of two polycytosine stretches interrupted by a thymidine
nucleotide. The number of cytosines at the first and second stretches are 7 and 5 respectively,
according to the GeneBank sequence. The first stretch exhibits a polymorphic length variation (6-
C to 9-C) among individuals and has been investigated in many cancer types. Large-scale studies are
needed to clarify the relationship between cytosine number and cancer development/progression.
However, time and money consuming methods such as radioactivity-based gel electrophoresis and
sequencing, are not appropriate for the determination of this polymorphism for large case-control
studies. In this study, we conducted a rapid RFLP analysis using a restriction enzyme, BsaXI, for the
single step simple determination of 7-C carriers at the first stretch in D310 region.
Methods: 25 colorectal cancer patients, 25 breast cancer patients and 41 healthy individuals were
enrolled into the study. PCR amplification followed by restriction enzyme digestion of D310 region
was performed for RFLP analysis. Digestion products were analysed by agarose gel electrophoresis.
Sequencing was also applied to samples in order to confirm the RFLP data.
Results: Samples containing 7-C at first stretch of D310 region were successfully determined by
the BsaXI RFLP method. Heteroplasmy and homoplasmy for 7-C content was also determined as
evidenced by direct sequencing. Forty-one percent of the studied samples were found to be BsaXI
positive. Furthermore, BsaXI status of colorectal cancer samples were significantly different from
that of healthy individuals.
Conclusion: In conclusion, BsaXI RFLP analysis is a simple and rapid approach for the single step
determination of D310 polymorphism of mitochondrial DNA. This method allows the evaluation
of a significant proportion of samples without the need for sequencing- and/or radioactivity-based
techniques.
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Human mitochondrial DNA (mtDNA) is composed of a
16.6 kb, double stranded, circular DNA molecule that
encodes 13 polypeptides of the respiratory chain, 22
transfer RNAs and 2 ribosomal RNAs [1]. Mitochondrial
DNA alterations have been suspected to play an impor-
tant role in the development and progression of cancer.
Several mutations have been identified in a wide variety of
human tumors, including breast, colorectal, ovarian, gas-
tric, hepatic and esophageal cancers, as well as hematolog-
ical malignancies [2-6]. D-loop region of the mtDNA is
the most potent accumulation site for many of these
mutations and numerous polymorphisms have also been
reported in this region. This is explained by the lack of
protective histones, high oxidative stress and deficient
DNA repair mechanisms [5]. D-loop is the only non-cod-
ing mtDNA region which contains crucial elements for
replication and transcription. Thus, the sequence altera-
tions of this region may contribute to altered replication
or transcription properties [4,5].
Recently, Sanches-Cespedes and colleagues have identi-
fied a polyC mononucleotide repeat located between 303
and 315 nucleotides within the D-loop region as a mito-
chondrial hot spot of deletion or insertion mutations [7].
This region is a part of the conserved sequence block
(CSB) II and consists of a stretch of cytosines interrupted
by a thymine nucleotide (CCCCCCCTCCCCC). Although
the number of cytosine residues at the first stretch of
polyC is accepted as 7-C (GeneBank NC_001807), it is
highly polymorphic ranging between 6-C to 9-C [1,8-10].
It is still questionable whether there is any correlation
between the number of cytosine residues and the develop-
ment and/or progression of cancer. Typically, time and
money consuming methods such as sequencing and radi-
oactivity-based gel electrophoresis are required in order to
evaluate this polymorphism among individuals. Moreo-
ver, gel electrophoresis remains ineffective unless con-
firmed with sequencing. Especially in large population
studies, these limidations become obviously important.
The aims of this study were to develop a restriction frag-
ment length polymorphism (RFLP) assay for the single
step rapid screening of individuals that carry first stretch 7-
C at mitochondrial D310 region and to evaluate if any dif-
ference exists among healthy individuals and cancer
patients in the Turkish population. We tested a total of
141 tissue samples including normal and cancerous tis-
sues of 25 breast and 25 colorectal cancer patients and 41
blood samples of healthy individuals. By applying this
simple approach without a need for sequencing and/or
radioactive labelling, 41% of the studied samples were
found to have 7-C in D310 region. Furthermore, we com-
pared the cases and normal samples for their RFLP status
and found a statistically significant difference between
colorectal cancer samples and healthy individuals.
Methods
Tissue specimens and DNA extraction
Paraffin embedded tissue specimens from primary tumors
and matched normal (adjacent non-neoplastic) tissues
were selected from 25 breast cancer and 25 colorectal can-
cer patients treated at Marmara University Hospital
between 1990–2003. Briefly, 6 µm thick sections were cut
from blocks that had been selected for maximal tumor
content. These sections from formalin-fixed paraffin-
embedded tissue blocks were deparaffinized first by wash-
ing with xylene, then with absolute ethanol. The depar-
affinized tissues were incubated at 55°C in 150 µL of
digestion buffer (0.5 mg/ml proteinase K; 0.05 M Tris-
HCl, pH 8.5; 1 mM EDTA; 0.5% Tween 20) for three
hours. Then the enzyme was inactivated by heating for 10
minutes at 94°C, and the samples were centrifuged at
12,000 g for 10 minutes. The supernatant containing total
genomic DNA was aliquoted and stored at -20°C [11].
Control DNA from blood samples of healthy volunteers
was also extracted by proteinase K digestion followed by
phenol/chloroform extraction according to John et al
[12]. The study protocol was approved by the Marmara
University Faculty of Medicine Research Ethics Commit-
tee.
Genotyping assays of D310 repeat
D310 region of mtDNA was amplified by polymerase
chain reaction (PCR) as described by Sanches-Cespedes et
al [7]. The primer sequences were as follows: forward 5-
ACAATTGAATGTCTTGCACAGCCACTT-3 and reverse 5-
GGCAGAGATGTGTTTAAGTGCTG-3. PCR amplications
were performed in a 50 µl volume containing 200 µM of
each dNTP, 12.5 pmol of each of the forward and reverse
primers, 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 1.5 mM
MgCl2 and 1 U of Taq DNA polymerase (Fermentas,
Lithuania). PCR cycling conditions were as follows: 96°C
for 90 s, followed by 40 cycles of 96°C for 30 s, 60°C for
30 s and 72°C for 30 s, then extension at 72°C for 5 min
(Biometra, UNO-Thermoblock model of thermocycler,
Germany). 109 bp PCR products were checked by 1.8%
agarose gel electrophoresis.
PCR products were subjected to restriction enzyme diges-
tion. 5 µl of PCR product was mixed with 3 U of BsaXI
(New England Biolabs, USA) in 1× buffer containing 50
mM potassium acetate, 20 mM tris-acetate, 10 mM mag-
nesium acetate, 1 mM DTT, pH 7.9. The samples were
incubated at 37°C for 19 hours to ensure complete diges-
tion. Restriction products were separated on 4% agarose
gel. Samples were also processed for DNA sequencing
using forward primer by fluorescence-based automatic
sequence analyzer (ABI PRISM 310, USA).Page 2 of 5
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was considered as statistically significant.
Results
We conducted an RFLP assay in order to determine 7-C
carrying individuals in mtDNA D310 region by eliminat-
ing the time-consuming sequencing method. We ampli-
fied D310 region and then exposed it to digestion with
BsaXI (Fig 1). The recognition sequence of the restriction
enzyme is ACNNNNNCTCC. If the sequence of the first
stretch of D310 region consists of 7-C, digestion occurs
and two bands appear on the agarose gel corresponding to
52 bp and 30/27 bp, referred as BsaXI positive (Fig 1A,
lane 1). A single band corresponding to 109 bp PCR prod-
uct is seen at the gel for BsaXI (-) cases (Fig 1A, lane 2). In
this state, number of cytosine residues is either more or
less than 7-C. At the heteroplasmic state, all of those
bands (109, 52, 30/27 bp) appear (Fig 1A, Lane 3). In
order to confirm this analysis, automated fluorescence
based sequencing was also applied and results of 3 cases
are given in Fig 1B. As seen in this figure, BsaXI digestion
was consistent with sequence analysis. It must be noted
that this approach allows only the determination of first
stretch of polyC with 7-C. Homoplasmic 7-C sequence of
BsaXI positive samples was confirmed by automated
sequence analysis (Fig 1B, upper panel). On the other
hand, the BsaXI negative sample (Fig 1A, lane 2) has pol-
ymorphic variants containing 8-C and 9-C in its mtDNA
pool (Fig 1B, middle panel). Finally, heteroplasmy for
BsaXI (Fig 1A, lane 3) showed that the patients have both
7-C and 8-C sequences (Fig 1B, lower panel).
Table 1 shows BsaXI RFLP status of 25 colorectal and 25
breast carcinoma samples with their surrounding normal
tissues and of blood samples from 41 healthy individuals
tested. In case of the breast cancer samples, 12 of 25
(48%) cases were BsaXI positive, whereas 11 patients were
BsaXI negative (44%) and 2 (8%) were heteroplasmic
(Table 1). On the other hand, heteroplasmy was not
encountered in corresponding healthy tissue samples.
A) Agarose gel electrophoresis of BsaXI digestion of 109 bp D310 region of 3 colorectal cancer patientsFigure 1
A) Agarose gel electrophoresis of BsaXI digestion of 109 bp D310 region of 3 colorectal cancer patients. Lane 1: BsaXI (+) 
Lane 2: BsaXI (-) Lane 3: Heteroplasmic B) Respective sequence analysis profiles: The upper: BsaXI (+) homoplasmy with 7-C at 
the first stretch; the middle: BsaXI (-) with 8 and 9-C heteroplasmy; the lower: Heteroplasmic for BsaXI digestion with 7 and 8-
C.
Table 1: Summary of BsaXI RFLP data.
Breast cancer Colorectal cancer Healthy individuals
n: 25 n: 25 n: 41
Mean age: 59.5 ± 13.8 Mean age: 62.4 ± 10.6 Mean age: 59.2 ± 11.9
Tumor (n) Control (n) Tumor (n) Control (n) (n)
Bsa XI (+) 12 13 9 10 14
BsaXI (-) 11 12 10 12 27
Heteroplasmy 2 0 6 3 0Page 3 of 5
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cancer samples showed the same digestion profile as their
corresponding healthy tissues. In these heteroplasmic
cases, one of the normal tissues surrounding the tumor
tissues was BsaXI positive and the other was negative.
Cases with different BsaXI status in tumor and its corre-
sponding normal tissues are shown in Table 2.
Regarding colorectal tumor samples, 9 out of 25 cases
(36%) were BsaXI positive and 10 cases (40%) were BsaXI
negative. Twenty-four percent (6/25) of the cases were
heteroplasmic for BsaXI digestion (Table 1). As seen in the
breast cancer samples, colorectal tumor samples had
almost the same digestion profile with that of the
matched normal tissues. On the other hand, three hetero-
plasmic and one homoplasmic BsaXI positive tumor sam-
ples showed different patterns than corresponding
normal tissue (Table 2). The tumor counterparts of two
BsaXI positive and one BsaXI negative normal tissues are
heteroplasmic. In the BsaXI positive tumor sample, the
corresponding normal tissue showed BsaXI negative gen-
otype (Table 2). Differences between tumor samples and
corresponding normal tissues were not statistically signif-
icant in either colorectal or breast cancer tissues (p > 0.05).
Forty-one healthy individuals (10 men and 31 women)
were also tested for D310 BsaXI RFLP analysis. No hetero-
plasmy was shown in these individuals. BsaXI positive
and negative cases were 34.1% (14/41) and 65.9% (27/
41), respectively (Table 1). We also compared BsaXI status
of the samples of patients with control samples from
healthy patients. Interestingly, when control group was
compared with the colorectal tumor group, there was a
statistically significant difference for BsaXI status (p =
0.003). However, BsaXI negative cases had lower fre-
quency in the breast cancer samples (11/25, 44%) when
compared to the control group (27/41, 65.9%), but this
difference was not statistically significant (p= 0.063). It
should be noted that males were excluded when compar-
ing the breast cancer cases with the healthy individuals to
make a gender match between the cases and controls.
Discussion
Recently, researchers have focused on mtDNA D-loop
alterations in a variety of human tumors. In the first
description by Sanches-Cespedes et al., the D310 region
of the D-loop was studied by a simple PCR based
approach following a radioactivity-based denaturating
polyacrylamide gel electrophoresis or direct sequencing
[7]. The authors reported that 22% of primary tumor sam-
ples showed D310 first polyC stretch alterations. Parrella
et al. reported sequence alterations in 19% of the breast
cancer samples and showed also the same alterations in
matched lymph node or fine needle aspirated samples [9].
Various percentages of D310 alterations were also
reported by several researchers in studies on thyroid,
breast, cervical and gastric cancers [10,13-15].
Radioactivity-based gel electrophoresis is widely used for
the determination of D310 first stretch polymorphism,
but this method has two important limitations. First of
all, the method can only detect the difference between
patients and control individuals, but the exact cytosine
number at the first stretch cannot be clarified unless con-
firmed by sequencing. Secondly, the use of radioactive
compounds makes this method inappropriate for large
population studies. Although sequencing is a gold stand-
ard for mutation research, it is a laborious and time-con-
suming method. Here, we tested a novel rapid pre-
screening RFLP method that may be useful for studies
with relatively large number of cases. As expected, a signif-
icant number of cases could be determined for the D310
first stretch status (41%) without need for sequencing
approach. Thus, by using this approach, a significant per-
centage of cases can be determined for their cytosine
number at the first stretch of D310 region and the remain-
ing cases may be further analysed by sequencing.
Although the relationship between BsaXI RFLP status and
tumor development is not clear, in this study a statistically
significant difference was found between colorectal cancer
patients and healthy individuals. Moreover, there was no
Table 2: Cases with different BsaXI status in tumor and corresponding normal tissues.
Tumor type Patient ID BsaXI Status
Tumor Normal
Breast cancer 1712 Heteroplasmy BsaXI (-)
2955 Heteroplasmy BsaXI (+)
Colorectal cancer 116 BsaXI (+) BsaXI (-)
779 Heteroplasmy BsaXI (-)
1619 Heteroplasmy BsaXI (+)
5367 Heteroplasmy BsaXI (+)Page 4 of 5
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significant difference between tumor samples and
matched normal tissues for BsaXI RFLP status. Cytosine
numbers may be different for BsaXI negative cases. Since
the digestion profile of a 6-C, an 8-C or a 9-C stretch are
the same, the method applied in this study allows to
determine the exact cytosine number only when it is 7.
In conclusion, determination of the BsaXI RFLP status of
D310 region of D-loop of mtDNA is a new, simple, cost-
effective and promising approach and can be applied for
the screening of large populations.
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